Literature DB >> 21272508

Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.

Christoph U Correll1.   

Abstract

Children and adolescents are at a greater risk than adults for antipsychotic-induced adverse effects such as extrapyramidal symptoms, prolactin elevation, sedation, weight gain, and metabolic effects, which can have long-term health consequences for young patients. Clinicians should complete careful baseline assessments and perform dietary and lifestyle counseling when initiating antipsychotic treatment and then proactively monitor for adverse effects to optimize physical as well as psychiatric outcomes. Strategies to manage adverse effects that occur or worsen during treatment include switching medications, lowering the dosage of medications, and initiating targeted treatments to address clinically relevant changes. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272508     DOI: 10.4088/JCP.9101tx6c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report.

Authors:  Hassan Mirza; Duncan Harding; Naser Al-Balushi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-09-09

Review 2.  A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.

Authors:  Rebecca C Harvey; Anthony C James; Gemma E Shields
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

Review 3.  Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.

Authors:  José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-17       Impact factor: 4.785

4.  An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.

Authors:  Gahan Pandina; Stuart Kushner; Keith Karcher; Magali Haas
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-06-07       Impact factor: 3.033

5.  The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services.

Authors:  Carol Paton; Clive E Adams; Stephen Dye; Elizabeth Fagan; Chike Okocha; Thomas Re Barnes
Journal:  J Psychopharmacol       Date:  2018-12-19       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.